Back to Results

AAML1831 - A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Study

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Kelly Maloney,  MD

Kelly Maloney, MD

Study ID

Protocol Number: 20-1864

More information available at ClinicalTrials.gov: NCT04293562

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers